When business owners and executives talk about economic threats to New Jersey, one recurring topic is the way that other states are luring away companies by offering lower taxes and fewer regulations. But soon after Dr. Marco Taglietti took over as chief executive officer of Scynexis — a publicly traded biotechnology company focusing on difficult-to-treat and often life-threatening infections — he concluded that a move to New Jersey would be the right strategy for the growing business. Read more here.